GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More
Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment
In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication for its cancer drug, Rubraca (rucaparib). This ... Read More
Refined white sugar may result in development of ovarian cancer in women
World Health Organisation says that refined white sugar can contribute to adverse health effects and it should be restricted in diet by 10 to 20 ... Read More
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More